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Cytochrome b5 reductase 2 suppresses 
tumor formation in nasopharyngeal carcinoma 
by attenuating angiogenesis
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Abstract 
Background: Cytochrome b5 reductase 2 (CYB5R2) is a potential tumor suppressor that inhibits cell proliferation and 
motility in nasopharyngeal carcinoma (NPC). Inactivation of CYB5R2 is associated with lymph node metastasis in NPC. 
This study aimed to explore the mechanisms contributing to the anti-neoplastic effects of CYB5R2.
Methods: Polymerase chain reaction (PCR) assays were used to analyze the transcription of 84 genes known to be 
involved in representative cancer pathways in the NPC cell line HONE1. NPC cell lines CNE2 and HONE1 were tran-
siently transfected with CYB5R2, and data was validated by real-time PCR. A chick chorioallantoic membrane (CAM) 
embryo model was implanted with CYB5R2-expressing CNE2 and HONE1 cells to evaluate the effect of CYB5R2 on 
angiogenesis. An immunohistochemical assay of the CAM model was used to analyze the protein expression of vas-
cular endothelial growth factor (VEGF).
Results: In CYB5R2-transfected NPC cells, PCR assays revealed up-regulated mRNA levels of Fas cell surface death 
receptor (FAS), FBJ murine osteosarcoma viral oncogene homolog (FOS), phosphoinositide-3-kinase regulatory subu-
nit 1 (PIK3R1), integrin beta 3 (ITGB3), metastasis suppressor 1 (MTSS1), interferon beta 1 (IFNB1), and cyclin-dependent 
kinase inhibitor 2A (CDKN2A) and down-regulated levels of integrin beta 5 (ITGB5), insulin-like growth factor 1 (IGF1), 
TEK tyrosine kinase (TEK), transforming growth factor beta receptor 1 (TGFBR1), and VEGF. The angiogenesis in the CAM 
model implanted with CYB5R2-transfected NPC cells was inhibited. Down-regulation of VEGF by CYB5R2 in NPC cells 
was confirmed by immunohistochemical staining in the CAM model.
Conclusion: CYB5R2 up-regulates the expression of genes that negatively modulate angiogenesis in NPC cells and 
down-regulates the expression of VEGF to reduce angiogenesis, thereby suppressing tumor formation.
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Background
Nasopharyngeal carcinoma (NPC) is a major health 
problem in South China, with a morbidity of 25–30 per 
100,000 people each year [1]. The etiology of NPC is 
closely related to environmental carcinogens, Epstein-
Barr virus (EBV) infection, and genetic susceptibility [2, 
3]. Inactivation of tumor suppressor genes (TSGs) by 
promoter DNA hypermethylation is frequently observed 
in patients with NPC and is considered to be a tumori-
genic factor of NPC [4].
Cytochrome b5 reductase 2 (CYB5R2), a nicotinamide 
adenine dinucleotide (NADH)-dependent flavin reduc-
tase, belongs to the cytochrome reductase family and has 
functions in oxidation reduction, drug metabolism, and 
methemoglobin reduction in erythrocytes [5]. A recent 
study has shown that CYB5R provides the electrons nec-
essary for turnover of fatty acid desaturase in the desatu-
ration process of fatty acids [6]. CYB5R may therefore be 
an important cofactor in lipid metabolism.
The expression of CYB5R2 varies in different types of 
cancer. CYB5R2 is abnormally inactivated in prostate and 
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breast cancers, and it regulates cell proliferation and dif-
ferentiation, similar to other TSGs [7, 8], but it is up-reg-
ulated in B cell acute lymphocytic leukemia [9].
In previous study, we showed that promoter DNA 
hypermethylation was responsible for inactivation of 
CYB5R2 and associated with lymph node metastasis in 
NPC patients [10]. In addition, exogenous expression of 
CYB5R2 significantly inhibited the proliferation, colony 
formation, migration, and in  vivo tumor formation of 
NPC cells, which suggests that CYB5R2 is a potential 
TSG of NPC [10]. However, the molecular mechanism by 
which CYB5R2 acts as a TSG has not been illustrated.
In the present study, we further explored the pathways 
affected by CYB5R2. Using polymerase chain reaction 
(PCR) assays of NPC cells transfected with CYB5R2, we 
investigated the changes in mRNA expression of 84 genes 
in 6 signaling pathways related to cancer. A chick chorio-
allantoic membrane (CAM) embryo model was used to 
validate the inhibitory effect of CYB5R2 on angiogenesis 
in NPC cell xenograft.
Methods
Cell culture and reagents
EBV-negative NPC cell lines CNE2 [11] and HONE1 
[12] were cultured in 6-well plates with 3 mL of Iscove’s 
modified Dulbecco’s medium (IMDM, Invitrogen, Carls-
bad, CA, USA) containing 10% newborn calf serum 
(Gibco, Grand Island, NY, USA), 100  U/mL penicillin, 
and 100 μg/mL streptomycin in a humidified atmosphere 
with 5% CO2 at 37°C.
PCR assay of cancer pathway genes
Total RNA was isolated from HONE1 cells, in which the 
transcription of CYB5R2 is almost silence, using Trizol 
(Invitrogen). First-strand cDNA was synthesized using 
M-MLV reverse transcriptase (Promega, Madison, WI, 
USA). The PAHS-033A Human Cancer Pathway Finder 
Superarray and Microsoft Excel-based data analysis soft-
ware (Qiagen, Dusseldorf, Germany) were used to iden-
tify changes in the mRNA expression of 84 genes that are 
representative of 6 signaling pathways: cell cycle control 
and DNA damage repair, apoptosis and cell senescence, 
signal transduction molecules and transcription fac-
tors, cell adhesion, angiogenesis and tumor invasion, and 
metastasis.
Vector construction and transfection
Full-length cDNA from the open reading frame of 
CYB5R2, purchased from Origen Co. (Beijing, China), 
was subcloned into the pCMV-Tag3A vector (Stratagene, 
La Jolla, CA, USA). CNE2 or HONE1 cells were seeded 
in 6-well plates (8 × 105 cells/well) and transfected with 
2  μg pCMV-Tag3A-CYB5R2 or pCMV-Tag3A (empty 
vector) plasmids using an X-treme GENE HP DNA 
Transfection Reagent (Roche Diagnostic, Penzberg, 
Germany) and incubated for 48 h. Each experiment was 
repeated three times.
Quantitative real‑time PCR
Significant modification of gene transcription by ectopic 
expression of CYB5R2 was further confirmed by quan-
titative real-time PCR. Primer information is in Table 1. 
GAPDH was amplified from the same cDNA samples 
and was used as an internal control. The PCR conditions 
were 95°C for 10 min, followed by 40 cycles at 95°C for 
30  s and 60°C for 1  min. Relative expression of target 
genes in CNE2 and HONE1 cells transfected with 
pCMV-Tag3A-CYB5R2 was determined by the 2−△△CT 
method as follows: Q =  2−ΔΔCT, ΔΔCT =  (CTtarget gene 
−  CTGAPDH)experimental  −  (CTtarget gene  −  CTGAPDH)control. 
Empty vector-transfected cells were used as the control. 
Independent experiments were performed in triplicate.
CAM assay
Twelve fertilized chicken eggs were incubated for 8 days 
at 37°C at 60% humidity. Briefly, a small hole was drilled 
into the eggshell where the air sac is located. For inoc-
ulation, a 1-cm2 window was carefully opened. An 
amount of 8  ×  105 CNE2 or HONE1 cells was resus-
pended in 10 μL of IMDM and seeded into a silicon ring 
(ϕ = 5 mm, homemade), which was then placed on the 
CAM. The window was covered with parafilm (Hons-
med, Shanghai, China), and the egg was placed back into 
the incubator. Silicone rings were removed 24 h later [13]. 
Tumor growth and vessels were observed daily using a 
SZ61 Zoom Stereo Microscope (Olympus, Tokyo, Japan). 
The area under the opened window and the vascular area 
were analyzed with Image-Pro Plus 5.0 (Media Cybernet-
ics, Rockville, MD, USA). Angiogenesis was quantified as 
the ratio of vascular area to total observed area. Micro-
tumors were removed from CAMs on day 5 after cell 
implantation, and the tumor volume was calculated as 
volume = width2 × length × 0.5 [14]. Tumors were fixed 
with 4% paraformaldehyde and embedded in paraffin.
Hematoxylin and Eosin (H&E) staining 
and immunohistochemistry (IHC assay)
H&E staining was performed following a standard pro-
tocol [15]. For immunohistochemical staining, sections 
(3  μm) were deparaffinized and rehydrated. Sections 
then underwent antigen retrieval with 0.01 mol/L sodium 
citrate, followed by blocking with 5% fetal bovine serum 
and incubation with 50  μL of ready-for-use monoclo-
nal antibody targeting vascular endothelial growth fac-
tor (VEGF) (MAB-0243, MAIXIN-BIO, Fuzhou, Fujian, 
China) at 4°C overnight. Sections were then exposed to 
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1:1,000 peroxidase-conjugated goat anti-mouse second-
ary antibody (ZB-2305, ZSGB-BIO, Beijing, China) at 
room temperature for 30 min, and signals were visualized 
using 3,3′-diaminobenzidine (DAB) reagent (ZSGB-BIO). 
Finally, sections were counterstained with hematoxy-
lin and images were acquired under a C-5050 Olympus 
microscope (Olympus).
Enzyme‑linked immunosorbent assay (ELISA)
ELISA of secreted VEGF was carried out following the 
manufacturer’s instructions (Sigma, Louis, MO, USA). 
Standard and cell culture supernatant (100 μL/well) was 
added to 96-well plates, and cells were incubated for 3 h 
at room temperature followed by coloration with horse-
radish peroxidase-conjugated streptavidin and 5′-tetra-
methylbenzidinev (TMB) reagent. Absorbance was 
measured using a microplate reader (Multiskan Fisher 
Scientific, Thermo, Waltham, MA, USA) at a wavelength 
of 450 nm. All samples were tested in triplicate.
Statistical analysis
Statistical analysis involved the use of SPSS version 16.0 
(SPSS Inc., Chicago, IL, USA). Data are shown as the 
mean  ±  standard deviation (SD) of 3 experiments. An 
independent sample t test was used to compare data. 
P < 0.05 was considered statistically significant.
Table 1 Primer sequences used in this study
CYB5R2 cytochrome b5 reductase 2, FAS Fas cell surface death receptor, FOS FBJ murine osteosarcoma viral oncogene homolog, PIK3R1 phosphoinositide-3-kinase 
regulatory subunit 1, ITGB3 integrin beta 3, MTSS1 metastasis suppressor 1, ITGB5 integrin beta 5, IFNB1 interferon beta 1, VEGF vascular endothelial growth factor, 
IGF1 insulin-like growth factor 1, TEK TEK tyrosine kinase, TGFBR1 transforming growth factor beta receptor 1, CDKN2A cyclin-dependent kinase inhibitor 2A, GAPDH 
glyceraldehyde-3-phosphate dehydrogenase, HIF-1α hypoxia-induced factor-1 alpha.
Primer Primer sequence (5′–3′) Product size (bp)
CYB5R2 Forward: AAACACTGGCCGATCACCT 150
Reverse: TGACCAAGATATCCTCCTCTGT
FAS Forward: CTGCCATAAGCCCTGTCCTCCA 199
Reverse: ATTCTGGGTCCGGGTGCAGTT
FOS Forward: TGGCAGGAGGGGCAAGGTGGA 240
Reverse: GCAGGTCGGTGAGCTGCCAGGATG
PIK3R1 Forward: CGGCAAAAGAAGTTGAACGAGTGG 347
Reverse: TGCACAAGGGAGGTGTGTTGGTAA
ITGB3 Forward: GTAACCTGCGGATTGGCTTCG 170
Reverse: GAAGCGGGTCACCTGGTCAGT
MTSS1 Forward: GTGGTGGGACCAGGGAGATTG 232
Reverse: TTCAGCGTATCCGAGGACTTCTT
ITGB5 Forward: CCGGCTCGCAGGTCTCAAC 306
Reverse: TCACCGGGCCGGAGGTTCAC
IFNB1 Forward: GCTCTCCTGTTGTGCTTCTCCACT 176
Reverse: AGCTGCTTAATCTCCTCAGGGATG
VEGF Forward: CTTCTGAGTTGCCCAGGAGACCACT 230
Reverse: TCAACCACTCACACACACACAACCA
IGF1 Forward: CAACAAGCCCACAGGGTATGGCT 173
Reverse: TGGGCATGTCGGTGTGGCGCT
TEK Forward: CAGGAGTTTGGGTCTGCAGTGTGA 383
Reverse: TGGAGGAGGGAGTCCGATAGAAGC
TGFBR1 Forward: GCATTGGCAAAGGTCGATTTGG 303
Reverse: TCGCCGTGGACAGAGCAAGTT
CDKN2A Forward: CGAAGGTCCTACAGGGCCACAAC 273
Reverse: CTCGCAAGAAATGCCCACATGAA
GAPDH Forward: AAGCTCACTGGCATGGCCTT 375
Reverse: CTCTCTTCCTCTTGTGCTCTTG
HIF-1α Forward: CCGAATTGATGGGATATGAG 150
Reverse: TCATGATGAGTTTTGGTCAGATG
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Results
CYB5R2 affected the expression of genes associated 
with apoptosis, cell cycle, angiogenesis, invasion, 
and metastasis of NPC cells
To determine the mechanisms involved in the tumor 
suppressive effect of CYB5R2 on NPC cells, we first 
confirmed that CYB5R2 mRNA level was increased in 
NPC cells (CNE2 and HONE1) after transfection with 
a CYB5R2 expression plasmid (Figure 1). We then used 
PCR assays to evaluate changes in the mRNA levels of 
84 genes related to cell proliferation, apoptosis, cell 
cycle, angiogenesis, invasion, and metastasis in HONE1 
cells that were transfected with CYB5R2 or an empty 
vector. The mRNA levels of 12 genes were significantly 
altered by CYB5R2 overexpression (up- or down-reg-
ulated by at least 1.5-fold compared with empty vector 
control) (Table  2). Several genes involved in apoptosis, 
signal transduction and transcription, cell cycle con-
trol, and DNA damage repair [Fas cell surface death 
receptor (FAS), FBJ murine osteosarcoma viral onco-
gene homolog (FOS), phosphoinositide-3-kinase regu-
latory subunit 1 (PIK3R1), and cyclin-dependent kinase 
inhibitor 2A (CDKN2A)] were up-regulated. Some genes 
involved in angiogenesis (vascular endothelial growth 
factor A (VEGFA) [16]), insulin-like growth factor 1 
(IGF1), TEK tyrosine kinase (TEK), and transforming 
growth factor beta receptor 1 (TGFBR1) were down-
regulated, whereas one, interferon beta 1 (IFNB1), was 
up-regulated. The mRNA levels of several genes involved 
in adhesion [integrin beta 3 (ITGB3), metastasis sup-
pressor 1 (MTSS1), and integrin beta 5 (ITGB5)] were 
up-regulated or down-regulated with CYB5R2 expres-
sion. These changes in the gene expression in CYB5R2-
transfected NPC cells (CNE2 and HONE1) was verified 
by real-time PCR (Figure 2).
Ectopic expression of CYB5R2 suppressed angiogenic 
capacity in NPC cells
To evaluate the influence of exogenously expressed 
CYB5R2 on the angiogenic capacity of NPC cells, we 
implanted CYB5R2-transfected CNE2 and HONE1 
cells into a CAM model to analyze the formation of 
tumors and angiogenesis. CYB5R2-transfected CNE2 
and HONE1 cells formed smaller tumors than empty 
Figure 1 Ectopic expression of cytochrome b5 reductase 2 (CYB5R2) 
in nasopharyngeal carcinoma (NPC) cell lines CNE2 and HONE1. 
Relative expression of CYB5R2 in NPC cell lines was confirmed 
by real-time polymerase chain reaction (PCR) 48 h after transfec-
tion of CYB5R2 or empty vector plasmids. Data are presented as 
mean ± standard deviation (SD) of three experiments. *P < 0.05.
Table 2 Genes up-regulated or down-regulated at least 1.5-fold by overexpression of CYB5R2 in HONE1 cells
Pathway Gene symbol Name of gene Fold change in expression
Apoptosis and cell senescence FAS Fas (tumor necrosis factor receptor superfamily member 6) 1.81
Signal transduction and transcription FOS FBJ murine osteosarcoma viral oncogene homolog 1.86
PIK3R1 Phosphoinositide-3-kinase regulatory subunit 1 (alpha) 1.57
Adhesion ITGB3 Integrin beta 3 (platelet glycoprotein IIIa, antigen CD61) 1.68
MTSS1 Metastasis suppressor 1 1.59
ITGB5 Integrin beta 5 −8.72
Angiogenesis IFNB1 Interferon beta 1, fibroblast 1.84
VEGFA Vascular endothelial growth factor A −1.69
IGF1 Insulin-like growth factor 1 (somatomedin C) −1.57
TEK TEK tyrosine kinase, endothelial −10.28
TGFBR1 Transforming growth factor beta receptor 1 −1.71
Cell cycle control and DNA damage repair CDKN2A Cyclin-dependent kinase inhibitor 2A 1.57
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vector- cells (Figure 3a, b), and this was consistent with 
our previous in vivo results in nude mice [10].
Empty vector-transfected CNE2 and HONE1 cells 
showed dramatically increased blood vessel forma-
tion around the tumor mass, whereas the density of 
vessels was decreased with CYB5R2 overexpression 
(Figure  3a, c). Neovascularization was calculated as 
5.3% for CYB5R2-transfected CNE2 cells and 5.1% for 
CYB5R2-transfected HONE1 cells, which were signifi-
cantly less than those for empty vector-transfected CNE2 
and HONE1 cells (16.6% and 13.5%, respectively, both 
P  <  0.001; Figure  3c). The mRNA level of CYB5R2 was 
higher in the xenografts derived from CYB5R2-trans-
fected CNE2 and HONE1 cells than from empty vector-
transfected cells (Figure 3d).
H&E staining revealed that the induction of microves-
sels with CYB5R2-transfected CNE2 and HONE1 
cell implantation in CAM was reduced compared 
with that empty vector-transfected cell implantation 
(Figure  4a). The protein level of VEGF was decreased 
in CYB5R2-expressing CNE2 and HONE1 cells, veri-
fying the inhibitory effect of CYB5R2 on angiogenesis 
(Figure 4b). Secreted VEGF protein was also reduced by 
overexpression of CYB5R2 in both CNE2 and HONE1 
cells (Figure  4c). Finally, hypoxia-induced factor alpha 
(HIF-1α), an important activator of VEGF expression, 
was suppressed by CYB5R2 overexpression (Figure  4d), 
which may explain the inhibitory effect of CYB5R2 on 
VEGF expression.
Figure 2 Real-time PCR confirmation of genes regulated by CYB5R2 in NPC cell lines CNE2 and HONE1. a Fas cell surface death receptor (FAS); b 
FBJ murine osteosarcoma viral oncogene homolog (FOS); c phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1); d integrin beta 3 (ITGB3); e 
metastasis suppressor 1 (MTSS1); f interferon beta 1 (IFNB1); g cyclin-dependent kinase inhibitor 2A (CDKN2A); h vascular endothelial growth factor 
A (VEGFA); i insulin-like growth factor 1 (IGF1); j TEK tyrosine kinase (TEK); k transforming growth factor beta receptor 1 (TGFBR1); l integrin beta 
(ITGB5). Data are presented as mean ± SD of three experiments. *P < 0.05.
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Discussion
We found, using PCR assays, that the overexpression 
of CYB5R2, a potential TSG, affected the transcrip-
tion of genes involved in several major cancer-related 
pathways, including apoptosis, cell cycle, cell adhesion, 
angiogenesis, and tumor invasion and metastasis. Five 
genes (VEGFA, IFNB1, IGF1, TEK, and TGFBR1) are 
associated with angiogenesis, which provides clues to 
the mechanism of the association between epigenetic 
inactivation of CYB5R2 and lymph node metastasis [10]. 
We focused on the effect of CYB5R2 on the formation of 
new vasculature in NPC. Ectopic expression of CYB5R2, 
by NPC cells implanted in a CAM model, inhibited angi-
ogenesis. Down-regulation of VEGF by CYB5R2 in NPC 
cells was confirmed by immunohistochemical staining 
in the CAM model. CYB5R2 overexpression in NPC 
cells up-regulated the expression of genes that nega-
tively modulate angiogenesis and down-regulated the 
expression of the pro-angiogenic factor VEGF, resulting 
in reduced angiogenesis and, thereby, a suppression of 
tumor formation.
The presence of palpable cervical lymph nodes is usu-
ally the first presenting symptom in NPC, indicating that 
NPC has a high propensity to invade the lymphatic sys-
tem and spread to the cervical lymph nodes. NPC cells 
may also spread to distant organs, including the lungs, 
liver, and bones, through the blood stream. Angiogenesis 
and lymphangiogenesis are essential for tumor growth 
and metastasis, which is primarily driven by VEGF. As 
a member of the platelet-derived growth factor fam-
ily, VEGF is the most influential stimulator of vascu-
lar endothelial growth during tumor angiogenesis [17]. 
VEGF is now considered to be the most potent angio-
genic factor and, therefore, a promising therapeutic target 
for treating cancer [18, 19]. VEGF is highly expressed in a 
variety of human tumors and is closely related to a poor 
outcome in patients with NPC [20, 21]. VEGF is regulated 
by HIF-1α [22] and by oncogene signaling factors includ-
ing platelet-derived growth factor, fibroblast growth 
factor, epidermal growth factor (EGF), tumor necro-
sis factor, and transforming growth factor-β [23]. VEGF 
binds primarily to VEGF receptor type 2 in endothelial 
Figure 3 CYB5R2 inhibits angiogenesis in NPC cell xenografts in a chick chorioallantoic membrane (CAM) model. a Representative images of xeno-
graft tumors and surrounding blood vessels at 5 days after implantation with CNE2 or HONE1 cells that were transfected with CYB5R2 expression 
plasmid or empty vector plasmid. b Tumor volume measured on images of a. c Blood vessel area measured on images of a. d Relative expression of 
CYB5R2 in tumors from CAM models at 5 days after implantation. Data are presented as mean ± SD of three experiments. *P < 0.05.
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cells, by which it stimulates angiogenesis by activating 
downstream signaling enzymes, including extracellular 
signal-regulated kinase 1/2, Akt, and endothelial nitric 
oxide synthase [24]. IFNB1 is an ISGylation modification 
inducer [25] that inhibits tumor angiogenesis by repress-
ing pro-angiogenic genes, including VEGF and matrix 
Figure 4 Overexpression of CYB5R2 in NPC cells inhibits angiogenesis and VEGF expression. a Hematoxylin and Eosin (H&E) staining of xenografts 
in paraffin-embedded sections with tumors from the CAM model. Black arrows point to microvessels around the tumor. b Immunohistochemical 
staining of VEGF in xenografts from the CAM model. Empty vector-transfected CNE2 and HONE1 cells are positive for VEGF. c Enzyme-linked immu-
nosorbent assay (ELISA) of secreted VEGF protein in supernatant from CYB5R2- or empty vector-transfected CNE2 and HONE1 cells. d Real-time PCR 
analysis of the relative mRNA level of hypoxia-induced factor alpha (HIF-1α) in CYB5R2- or empty vector-transfected CNE2 and HONE1 cells. Data are 
presented as mean ± SD of three experiments. *P < 0.05.
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metalloproteinase 9 [26]. IGF1 and TGFBR1 play impor-
tant roles in inducing angiogenesis by increasing the level 
of VEGF [27–29]. TEK encodes a receptor that has 2 Ig-
like domains, 3 EGF-like domains, and 3 fibronectin type 
III repeats and functions in inducing blood vessel growth 
and affecting the establishment, growth, and metastasis 
of tumors through activation of the Akt signaling path-
way [30, 31].
We found that CYB5R2 expression in NPC cells 
altered the angiogenic balance by down-regulating 
a series of angiogenesis-promoting factors (VEGFA, 
IGF1, TGFBR1, and TEK) and up-regulating an angio-
genesis inhibitor, IFNB1. These data imply that CYB5R2 
plays a role in angiogenic suppression. To further 
investigate this role, we used CAM, an in  vivo model, 
to study tumor growth and angiogenesis and to evalu-
ate the effect of CYB5R2 on angiogenesis [32, 33]. 
CYB5R2-transfected CNE2 and HONE1 cell xenografts 
were smaller than empty vector-transfected CNE2 and 
HONE1 cell xenografts. Angiogenesis on the surface 
of the growing CAM was significantly suppressed in 
CYB5R2-expressing NPC cell xenografts. VEGF pro-
tein levels in xenografts and secreted VEGF protein 
levels from NPC cells were both reduced by CYB5R2 
overexpression. This provides further support for a role 
of CYB5R2 in the down-regulation of VEGF mRNA 
levels and subsequent reduction in angiogenesis. The 
transcription of HIF-1α was also significantly down-
regulated by CYB5R2 in NPC cells, which may further 
explain the down-regulation of VEGF by CYB5R2. 
CYB5R2 may therefore suppress tumor angiogenesis, 
but the detailed molecular mechanism has not yet been 
fully explained.
In summary, CYB5R2 transfection in NPC cells affected 
mRNA levels of several factors involved in angiogenesis, 
including VEGF, IFNB1, IGF1, TEK, and TGFBR1. When 
we overexpressed CYB5R2 in NPC cells and implanted 
these cells into a CAM model, cell proliferation and angi-
ogenesis were suppressed. The malignant phenotype may 
be inhibited by CYB5R2 through a down-regulation of 
VEGF or suppression of HIF-1α expression. Inactivation 
of CYB5R2 may contribute to angiogenesis in NPC. The 
results of this study provide insight into the mechanism 
by which CYB5R2 acts to suppress tumor function, and 
further support CYB5R2 as a novel TSG in NPC.
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